These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1223 related articles for article (PubMed ID: 37005490)

  • 21. Breast cancer models: Engineering the tumor microenvironment.
    Bahcecioglu G; Basara G; Ellis BW; Ren X; Zorlutuna P
    Acta Biomater; 2020 Apr; 106():1-21. PubMed ID: 32045679
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Integration of chemokine signaling with non-coding RNAs in tumor microenvironment and heterogeneity in different cancers.
    Arora S; Khan S; Zaki A; Tabassum G; Mohsin M; Bhutto HN; Ahmad T; Fatma T; Syed MA
    Semin Cancer Biol; 2022 Nov; 86(Pt 2):720-736. PubMed ID: 35257861
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hyperbaric oxygen facilitates teniposide-induced cGAS-STING activation to enhance the antitumor efficacy of PD-1 antibody in HCC.
    Li K; Gong Y; Qiu D; Tang H; Zhang J; Yuan Z; Huang Y; Qin Y; Ye L; Yang Y
    J Immunother Cancer; 2022 Aug; 10(8):. PubMed ID: 36002188
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Addressing CPI resistance in NSCLC: targeting TAM receptors to modulate the tumor microenvironment and future prospects.
    Peters S; Paz-Ares L; Herbst RS; Reck M
    J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35858709
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Beyond Cell Motility: The Expanding Roles of Chemokines and Their Receptors in Malignancy.
    Morein D; Erlichman N; Ben-Baruch A
    Front Immunol; 2020; 11():952. PubMed ID: 32582148
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dual inhibition of TGF-β and PD-L1: a novel approach to cancer treatment.
    Gulley JL; Schlom J; Barcellos-Hoff MH; Wang XJ; Seoane J; Audhuy F; Lan Y; Dussault I; Moustakas A
    Mol Oncol; 2022 Jun; 16(11):2117-2134. PubMed ID: 34854206
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Exploring the Emerging Role of the Gut Microbiota and Tumor Microenvironment in Cancer Immunotherapy.
    Qiu Q; Lin Y; Ma Y; Li X; Liang J; Chen Z; Liu K; Huang Y; Luo H; Huang R; Luo L
    Front Immunol; 2020; 11():612202. PubMed ID: 33488618
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The regulation of immune checkpoints by the hypoxic tumor microenvironment.
    Hu M; Li Y; Lu Y; Wang M; Li Y; Wang C; Li Q; Zhao H
    PeerJ; 2021; 9():e11306. PubMed ID: 34012727
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Synchronous targeted delivery of TGF-β siRNA to stromal and tumor cells elicits robust antitumor immunity against triple-negative breast cancer by comprehensively remodeling the tumor microenvironment.
    Yang M; Qin C; Tao L; Cheng G; Li J; Lv F; Yang N; Xing Z; Chu X; Han X; Huo M; Yin L
    Biomaterials; 2023 Oct; 301():122253. PubMed ID: 37536040
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Chemokine-Cytokine Networks in the Head and Neck Tumor Microenvironment.
    Nisar S; Yousuf P; Masoodi T; Wani NA; Hashem S; Singh M; Sageena G; Mishra D; Kumar R; Haris M; Bhat AA; Macha MA
    Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33925575
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mechanisms and pathways of innate immune activation and regulation in health and cancer.
    Cui J; Chen Y; Wang HY; Wang RF
    Hum Vaccin Immunother; 2014; 10(11):3270-85. PubMed ID: 25625930
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Intratumoral regulatory T cells: markers, subsets and their impact on anti-tumor immunity.
    Yano H; Andrews LP; Workman CJ; Vignali DAA
    Immunology; 2019 Jul; 157(3):232-247. PubMed ID: 31087644
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The tumor microenvironment: shaping cancer progression and treatment response.
    Desai SA; Patel VP; Bhosle KP; Nagare SD; Thombare KC
    J Chemother; 2024 Jan; ():1-30. PubMed ID: 38179655
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Multiple Interactions Between Cancer Cells and the Tumor Microenvironment Modulate TRAIL Signaling: Implications for TRAIL Receptor Targeted Therapy.
    de Looff M; de Jong S; Kruyt FAE
    Front Immunol; 2019; 10():1530. PubMed ID: 31333662
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tumor-targeted interleukin-12 synergizes with entinostat to overcome PD-1/PD-L1 blockade-resistant tumors harboring MHC-I and APM deficiencies.
    Minnar CM; Chariou PL; Horn LA; Hicks KC; Palena C; Schlom J; Gameiro SR
    J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35764364
    [TBL] [Abstract][Full Text] [Related]  

  • 36. High-throughput microfluidic 3D biomimetic model enabling quantitative description of the human breast tumor microenvironment.
    Berger Fridman I; Kostas J; Gregus M; Ray S; Sullivan MR; Ivanov AR; Cohen S; Konry T
    Acta Biomater; 2021 Sep; 132():473-488. PubMed ID: 34153511
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Tumor Microenvironment: Signal Transduction.
    Zhang X; Ma H; Gao Y; Liang Y; Du Y; Hao S; Ni T
    Biomolecules; 2024 Apr; 14(4):. PubMed ID: 38672455
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CXCL3 Signaling in the Tumor Microenvironment.
    Reyes N; Figueroa S; Tiwari R; Geliebter J
    Adv Exp Med Biol; 2021; 1302():15-24. PubMed ID: 34286438
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cellular interactions in tumor microenvironment during breast cancer progression: new frontiers and implications for novel therapeutics.
    Akinsipe T; Mohamedelhassan R; Akinpelu A; Pondugula SR; Mistriotis P; Avila LA; Suryawanshi A
    Front Immunol; 2024; 15():1302587. PubMed ID: 38533507
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inhibition of the CCL5/CCR5 Axis against the Progression of Gastric Cancer.
    Aldinucci D; Casagrande N
    Int J Mol Sci; 2018 May; 19(5):. PubMed ID: 29772686
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 62.